Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results
Portfolio Pulse from
Aytu BioPharma reported its fiscal 2025 Q2 results, showing a net income of $0.8 million and an adjusted EBITDA of $1.3 million. The company's pediatric portfolio net revenue increased by 86% sequentially, marking the first quarterly sequential prescription increase for both ADHD and pediatric portfolios since Q2 fiscal 2023. Aytu holds a $20.4 million cash balance as of December 31, 2024.
February 12, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aytu BioPharma reported a net income of $0.8 million and an adjusted EBITDA of $1.3 million for fiscal 2025 Q2. The pediatric portfolio net revenue increased by 86% sequentially, with the first prescription increase for ADHD and pediatric portfolios since Q2 fiscal 2023. The company has a $20.4 million cash balance.
The positive financial results, including net income and significant revenue growth in the pediatric portfolio, suggest a strong performance for Aytu BioPharma. The first prescription increase for ADHD and pediatric portfolios since Q2 fiscal 2023 indicates potential growth momentum. The $20.4 million cash balance provides financial stability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100